as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹979.1
Change
+21.0 (2.19%)
Open
₹958.1
Prev. Close
₹958.1
Day High
₹984.9
Day Low
₹952.3
Volume Analysis
Traded
388,914
Delivered
198,064
Delivery %
50.93%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (2)
- •Strong return on equity (20.0%)
- •Promoter holding is rising
Weaknesses (0)
No signal for this stock
Opportunities (1)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹1,024.5 | ₹1,004.7 | ₹991.9 | ₹972.1 | ₹959.3 | ₹939.5 | ₹926.7 |
| Fibonacci | ₹1,004.7 | ₹992.25 | ₹984.55 | ₹972.1 | ₹959.65 | ₹951.95 | ₹939.5 |
| Camarilla | ₹988.07 | ₹985.08 | ₹982.09 | ₹972.1 | ₹976.11 | ₹973.12 | ₹970.14 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
+7.43%
1 Week
-2.99%
1 Month
-4.51%
3 Months
-0.72%
6 Months
-15.1%
1 Year
+6.03%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹709.71
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
17.4%
Net margin 12.22% × asset turnover 0.65x × equity multiplier 2.19x
Company Overview
Sector
Healthcare
Market Cap
₹9,353 Cr
P/E (TTM)
16.2
ROE
20.0%
Book Value
₹371.0
Face Value
₹10.0
Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.
TopFund Analysis
Strides Pharma Sci Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (85/100), while Momentum (50/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (20.0%); promoter holding is rising. FII holding has been rising.
TopFund Score — Fundamentals Quality
65/100 — GoodData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has delivered good profit growth of 20.1% CAGR over last 5 years
- +Company has a good return on equity (ROE) track record: 3 Years ROE 57.0%
- −Stock is trading at 2.74 times its book value
- −The company has delivered a poor sales growth of 7.94% over past five years.
- −Promoter holding is low: 29.0%
- −Promoters have pledged 33.8% of their holding.
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Transcript of Earnings Call pertaining of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026
Newspaper Advertisement - Unaudited Financial Results for the quarter and half year ended September 30, 2026
Audio recording of earnings call for Q2 and H1 FY2026 results available on website.
Allotment of Equity shares pursuant to exercise of Stock Options.
Board appointed Biren Gabhawala as Non-Executive Independent Director from November 1, 2026 for five years.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 999 | 1,006 | 1,044 | 1,054 | 1,167 | 1,154 | 1,190 | 1,120 | 1,221 | 1,195 | 1,323 | 1,265 | 1,430 |
| Expenses + | 889 | 876 | 874 | 866 | 983 | 943 | 973 | 902 | 990 | 959 | 1,084 | 1,037 | 1,179 |
| Operating Profit | 111 | 129 | 169 | 188 | 184 | 210 | 218 | 218 | 231 | 236 | 240 | 228 | 251 |
| OPM % | 11.0% | 13.0% | 16.0% | 18.0% | 16.0% | 18.0% | 18.0% | 19.0% | 19.0% | 20.0% | 18.0% | 18.0% | 18.0% |
| Other Income + | -129 | 60 | -27 | 3,299 | 25 | 4 | -12 | 0 | 18 | 104 | 3 | 68 | 3 |
| Interest | 79 | 70 | 71 | 73 | 74 | 52 | 50 | 47 | 46 | 43 | 42 | 41 | 47 |
| Depreciation | 60 | 49 | 48 | 47 | 48 | 48 | 49 | 49 | 50 | 51 | 53 | 56 | 57 |
| Profit before tax | -157 | 70 | 23 | 3,369 | 86 | 114 | 106 | 122 | 153 | 245 | 148 | 200 | 150 |
| Tax % | -5.0% | 23.0% | 55.0% | 1.0% | 16.0% | 21.0% | 20.0% | 13.0% | 14.0% | 15.0% | 13.0% | 17.0% | 11.0% |
| Net Profit + | -149 | 54 | 10 | 3,350 | 72 | 90 | 86 | 106 | 132 | 208 | 129 | 165 | 134 |
| EPS in Rs | -15 | 5 | 2 | 365 | 8 | 10 | 9 | 11 | 14 | 22 | 14 | 17 | 14 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 11 | 16 | 6 | 13 | 17 | 15 | 14 | 6 | 5 | 4 | 11 | 13 | 17 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,196 | 2,861 | 2,755 | 2,845 | 2,178 | 2,752 | 3,316 | 3,070 | 3,688 | 3,890 | 4,565 | 4,859 | 5,213 |
| Expenses + | 967 | 2,486 | 2,228 | 2,448 | 1,982 | 2,338 | 2,779 | 3,201 | 3,544 | 3,362 | 3,763 | 3,933 | 4,258 |
| Operating Profit | 229 | 374 | 527 | 398 | 197 | 414 | 537 | -131 | 145 | 528 | 803 | 925 | 955 |
| OPM % | 19.0% | 13.0% | 19.0% | 14.0% | 9.0% | 15.0% | 16.0% | -4.3% | 3.9% | 14.0% | 18.0% | 19.0% | 18.0% |
| Other Income + | 874 | 63 | 291 | 643 | 303 | -43 | 109 | -112 | 92 | -100 | 3,313 | 124 | 178 |
| Interest | 47 | 168 | 183 | 196 | 79 | 156 | 150 | 177 | 261 | 280 | 249 | 179 | 172 |
| Depreciation | 64 | 131 | 126 | 154 | 117 | 174 | 206 | 233 | 243 | 214 | 192 | 202 | 217 |
| Profit before tax | 992 | 137 | 509 | 690 | 303 | 42 | 289 | -653 | -268 | -65 | 3,675 | 669 | 744 |
| Tax % | 15.0% | 31.0% | 12.0% | 1.0% | -9.0% | 27.0% | 11.0% | -27.0% | -21.0% | 45.0% | 2.0% | 14.0% | — |
| Net Profit + | 844 | 95 | 446 | 684 | 330 | 31 | 258 | -474 | -212 | -94 | 3,598 | 575 | 637 |
| EPS in Rs | 142 | 12 | 45 | 74 | 36 | 4 | 30 | -51 | -22 | -8 | 390 | 60 | 67 |
| Dividend Payout % | 76.0% | 41.0% | 10.0% | 3.0% | 8.0% | 345.0% | 8.0% | 0.0% | -7.0% | -33.0% | 1.0% | 8.0% | — |
| Sales growth | -11 | 139 | -4 | 3 | -23 | 26 | 20 | -7 | 20 | 5 | 17 | 6 | 11 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 1,085 | 2,569 | 2,659 | 2,374 | 2,559 | 2,438 | 2,687 | 2,269 | 2,122 | 2,034 | 2,460 | 3,015 | 3,324 |
| Borrowings + | 892 | 3,542 | 3,700 | 2,520 | 3,221 | 2,235 | 2,348 | 3,025 | 3,030 | 2,517 | 1,880 | 1,758 | 1,905 |
| Other Liabilities + | 438 | 1,211 | 1,598 | 1,601 | 1,937 | 1,369 | 1,844 | 1,556 | 1,352 | 1,157 | 1,498 | 1,941 | 2,167 |
| Total Liabilities | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 | 6,807 | 7,489 |
| Fixed Assets + | 701 | 2,679 | 2,980 | 2,977 | 3,648 | 2,099 | 2,219 | 2,347 | 2,311 | 1,865 | 1,899 | 2,101 | 2,406 |
| CWIP | 171 | 815 | 780 | 620 | 453 | 413 | 447 | 291 | 151 | 162 | 207 | 447 | 226 |
| Investments | 630 | 1,341 | 1,525 | 588 | 702 | 549 | 697 | 540 | 490 | 303 | 409 | 291 | 346 |
| Other Assets + | 972 | 2,576 | 2,762 | 2,400 | 3,005 | 3,070 | 3,605 | 3,762 | 3,642 | 3,470 | 3,414 | 3,967 | 4,510 |
| Total Assets | 2,475 | 7,410 | 8,046 | 6,585 | 7,807 | 6,131 | 6,969 | 6,940 | 6,594 | 5,799 | 5,929 | 6,807 | 7,489 |
| Equity Capital | 60 | 89 | 89 | 90 | 90 | 90 | 90 | 90 | 90 | 92 | 92 | 92 | 92 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 83 | 73 | 288 | 187 | 60 | 205 | 481 | -258 | 44 | 701 | 684 | 703 |
| Cash from Investing Activity + | 50 | -2,205 | -1,222 | 570 | -145 | 1,321 | -522 | -119 | 302 | -150 | -90 | -173 |
| Cash from Financing Activity + | -421 | 2,944 | 338 | -1,016 | 194 | -1,709 | -16 | 421 | -214 | -693 | -643 | -453 |
| Net Cash Flow | -288 | 812 | -596 | -259 | 110 | -184 | -56 | 45 | 133 | -142 | -48 | 76 |
| Free Cash Flow | -157 | -293 | -386 | -212 | -256 | 58 | 188 | -326 | -43 | 672 | 505 | 291 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 61 | 40 | 66 | 61 | 59 | 60 | 60 | 199 | -30 | 128 | 77 | 84 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 33.75% | 31.52% | 28.87% | 25.83% | 27.78% | 29.65% | 30.38% | 30.62% | 29.59% | 28.96% | 28.28% | 27.52% |
| Promoters | 27.39% | 25.88% | 25.86% | 25.84% | 26.82% | 28.3% | 28.3% | 27.86% | 27.86% | 27.91% | 27.91% | 29.0% |
| Government | 0.39% | 0.39% | 0.39% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| FII | 19.45% | 24.57% | 26.71% | 30.08% | 28.48% | 28.32% | 28.02% | 28.51% | 29.52% | 28.68% | 28.4% | 27.98% |
| DII | 19.02% | 17.66% | 18.17% | 18.24% | 16.92% | 13.72% | 13.3% | 12.98% | 13.02% | 14.44% | 15.42% | 15.51% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Strides Pharma Sci Ltd (this stock) | 9,353 | 16.2 | 2.74 | 20.0% |
| Paras Healthcare Limited | 9,284 | 129.0 | — | 13.0% |
| Aarti Pharmalabs Limited | 9,212 | 35.4 | 4.08 | 8.59% |
| Jupiter Life Line Hosp L | 9,507 | 50.0 | 5.84 | 13.1% |
| Blue Jet Healthcare Ltd | 9,989 | 70.9 | — | 52.1% |
| Healthcare Glob. Ent. Ltd | 8,562 | 216.0 | 6.36 | 2.54% |
| Yatharth Hosp & Tra C S L | 10,222 | 53.6 | 5.44 | 10.2% |
Which Mutual Funds Hold Strides Pharma Sci Ltd?
Frequently Asked Questions about Strides Pharma Sci Ltd
Strides Pharma Sci Ltd (STAR) closed at ₹979.1 on NSE on 19 November 2026, up 21.0 (2.19%) from the previous close.
Strides Pharma Sci Ltd trades on the NSE (National Stock Exchange of India) under the symbol STAR.
Strides Pharma Sci Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 16.2.
Strides Pharma Sci Ltd has a dividend yield of 0.49%.
Strides Pharma Sci Ltd's 52-week high is ₹1,261.0 and its 52-week low is ₹769.0.
Strides Pharma Sci Ltd has a market capitalisation of ₹9,353 crore.
Strides Pharma Sci Ltd has a TopFund Quality Score of 65/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Strides Pharma Sci Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.